α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment.

In addition to amyloid-β (Aβ) and tau, α-synuclein, best known for its role in Parkinson's disease (PD), has been suggested to be involved in cognition and pathogenesis of Alzheimer's disease (AD). We investigate the potential of α-synuclein in cerebrospinal fluid (CSF) as a biomarker of cognitive decline in AD, and its prodromal phase, mild cognitive impairment (MCI). Using an established, sensitive Luminex assay, we measured α-synuclein levels in the CSF of a cohort of close to 400 healthy control, MCI, and AD subjects obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and factored in APOE genotype in data analysis. CSF α-synuclein levels were significantly higher in the MCI (p = 0.005) and AD (p < 0.001) groups, compared to controls. However, receiver operating characteristic (ROC) curve analysis suggests that CSF α-synuclein level on its own only offered modest sensitivity (65%) and specificity (74%) as a diagnostic marker of AD, with an area under the curve (AUC) value of 0.719 for AD versus controls. The effect of APOE genotype, if any, was quite subtle. However, there was a significant correlation between α-synuclein and cognition (p = 0.001), with increased α-synuclein levels associated with decreased Mini-Mental State Exam scores. Our results support a role for α-synuclein even in MCI, the early phase of AD, in addition to being a potential contributor in MCI and AD diagnosis or monitoring of disease progression.

[1]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[2]  W. Spooren,et al.  Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice , 2007, Neurobiology of Aging.

[3]  L. Minthon,et al.  Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy , 2013, PloS one.

[4]  T. Südhof,et al.  A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides , 2008, Nature Neuroscience.

[5]  E. Masliah,et al.  A Pathologic Cascade Leading to Synaptic Dysfunction in α-Synuclein-Induced Neurodegeneration , 2010, The Journal of Neuroscience.

[6]  L. Thal,et al.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease , 1998, Neurology.

[7]  K. Jellinger.  Interaction between α-Synuclein and Other Proteins in Neurodegenerative Disorders , 2011, TheScientificWorldJournal.

[8]  J. Meldolesi,et al.  The regulation of synaptic function by α-synuclein , 2010 .

[9]  H. Soininen,et al.  Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. , 2003, Journal of neuropathology and experimental neurology.

[10]  J. Haines,et al.  Apolipoprotein E controls the risk and age at onset of Parkinson disease , 2004, Neurology.

[11]  S. Shan,et al.  NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease , 2011, Neurobiology of Aging.

[12]  K. Blennow,et al.  Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? , 2009, Neuroscience Letters.

[13]  J. Trojanowski,et al.  Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.

[14]  D. Dickson,et al.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[15]  J. Trojanowski,et al.  Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline , 2010, The Journal of Neuroscience.

[16]  D. Bennett,et al.  Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology , 2012, The Journal of Neuroscience.

[17]  W. M. van der Flier,et al.  CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[18]  A. Goris,et al.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease , 2009, Journal of Neurology.

[19]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Hol,et al.  Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis , 2012, Parkinson's disease.

[21]  D. Bennett,et al.  Decreases in soluble α-synuclein in frontal cortex correlate with cognitive decline in the elderly , 2004, Neuroscience Letters.

[22]  C. Poole,et al.  APOE-ϵ2 allele associated with higher prevalence of sporadic Parkinson disease , 2004 .

[23]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[24]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[25]  C. Finch,et al.  Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. , 1999, Alzheimer disease and associated disorders.

[26]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[28]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[29]  E M Wijsman,et al.  Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. , 1996, American journal of human genetics.

[30]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[31]  Xuemei Huang,et al.  Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. , 2006, Archives of neurology.

[32]  E. Masliah,et al.  Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases , 2008, PloS one.

[33]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[34]  E. Tolosa,et al.  Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease , 2008, Neuroscience Letters.

[35]  R. Sakakibara,et al.  Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease , 2012, Alzheimer disease and associated disorders.

[36]  G. Asano,et al.  α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation , 2001, Brain Research.

[37]  W. Potter.  Mining the secrets of the CSF: developing biomarkers of neurodegeneration. , 2012, The Journal of clinical investigation.

[38]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[39]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[40]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .